Siren Biotechnology

Siren Biotechnology operates in the biopharmaceutical market, specifically within the niche of cancer therapeutics. The company serves a diverse range of clients, including healthcare providers, research institutions, and ultimately, cancer patients who are in dire need of more effective treatment options. Their primary goal is to address the significant unmet medical needs in the oncology sector by developing therapies that can overcome the limitations of past treatments.

The business model of Siren Biotechnology is centered around research and development (R&D) of their proprietary AAV immuno gene therapy. They invest heavily in scientific research to advance their treatment modalities from the lab to clinical trials, and eventually to market. The company generates revenue through a combination of funding from venture capital, partnerships with pharmaceutical companies, and potentially, future sales of their approved therapies.

Siren Biotechnology makes money by securing investments from venture capital firms, forming strategic partnerships with larger pharmaceutical companies, and through the eventual commercialization of their therapies. By bringing their innovative treatments to market, they aim to not only improve patient outcomes but also achieve financial sustainability and growth.

In summary, Siren Biotechnology is dedicated to changing the landscape of cancer treatment through cutting-edge AAV gene therapy and cytokine immunotherapy. Their focus on brain and eye tumors positions them uniquely in the oncology market, with a strong emphasis on R&D and strategic partnerships to drive their business forward.